A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

Published:2022-04-20 Issue:9 Volume:63 Page:2161-2170
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Short Nicholas J.¹^ORCID,Borthakur Gautam¹^ORCID,Pemmaraju Naveen¹,Dinardo Courtney D.¹,Kadia Tapan M.¹,Jabbour Elias¹,Konopleva Marina¹,Macaron Walid¹^ORCID,Ning Jing²,Ma Junsheng²,Pierce Sherry¹,Alvarado Yesid¹,Sasaki Koji¹^ORCID,Takahashi Koichi¹,Estrov Zeev¹^ORCID,Masarova Lucia¹^ORCID,Issa Ghayas C.¹,Montalban-Bravo Guillermo¹,Andreeff Michael¹,Burger Jan A.¹,Miller Darla¹,Alexander Lynette¹,Naing Aung³,Garcia-Manero Guillermo¹,Ravandi Farhad¹,Daver Naval¹

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Funder

Pfizer and the healthcare business of Merck KGaA, Darmstadt, Germany.

MD Anderson Cancer Center Support Grant

SPORE

the K12 Paul Calabresi Clinical Oncology Scholar Award

American Society of Hematology Junior Faculty Scholar Award in Clinical Research

Dick Clark Immunotherapy Fund and the MD Anderson Cancer Center Faculty Scholar Award

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2062345

Reference42 articles.

1. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges

2. New directions for emerging therapies in acute myeloid leukemia: the next chapter

3. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

4. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

5. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies;Discover Oncology;2024-07-26

2. Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta‐Analysis of Observational Studies and Randomized Controlled Trials;Journal of the American Heart Association;2024-05-21

3. Decrease and impaired function of circulating mucosa-associated invariant T cells in acute myeloid leukemia;2024-03-28

4. OX40/OX40 ligand and its role in precision immune oncology;Cancer and Metastasis Reviews;2024-03-25

5. Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake;Frontiers in Immunology;2024-02-19